GHB, GBL and 1,4-BD Addiction

Author(s): Tibor M. Brunt, Jan G. C. van Amsterdam, Wim van den Brink.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 25 , 2014

Become EABM
Become Reviewer

Abstract:

A growing body of evidence shows that gamma-hydroxybutyric acid (GHB) is an addictive substance. Its precursors gammabutyrolactone (GBL) and 1,4-butanediol (1,4-BD) show the same properties and may pose even more risks due to different pharmacokinetics. There are indications that problematic GHB use is increasing in the European Union. This review investigates the existing literature on the neurochemistry of GHB and its precursors, their acute toxicity, addiction potential and withdrawal, the proposed molecular mechanism underlying addiction and the treatment of withdrawal and addiction. Current evidence shows that GHB and its precursors are highly addictive, both in humans and animals, probably through a GABAB receptor related mechanism. Severity of withdrawal symptoms can be considered as a medical emergency. Recent studies suggest that benzodiazepines are not very effective, showing a high treatment resistance, whereas detoxification with pharmaceutical GHB proved to be successful. However, relapse in GHB use is frequent and more research is warranted on relapse prevention. This might aid medical practitioners in the field and improve general understanding of the severity of addiction to GHB, GBL and 1,4-BD.

Keywords: GHB, GBL, 1, 4-BD, GABA, dopamine, illicit drugs, addiction, dependence, withdrawal.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 25
Year: 2014
Page: [4076 - 4085]
Pages: 10
DOI: 10.2174/13816128113199990624
Price: $58

Article Metrics

PDF: 32